Why Intuitive Stocks Command Premium Valuations: A Deeper Look

Intuitive Surgical enters 2026 with impressive operational momentum. The company deployed 532 surgical robots in the fourth quarter, representing growth from the 493 units placed in Q4 2024. The global installed base now stands at 11,106 da Vinci systems—a notable 12% year-over-year increase. For investors evaluating intuitive stocks and their place in a portfolio, understanding what drives these numbers is critical.

The Revenue Engine: It’s Not About Robot Sales

Most investors assume that selling surgical robots generates the bulk of Intuitive’s revenue. The reality tells a different story. Robot sales alone accounted for approximately 25% of total revenue in 2025, consistent with the prior year’s 24%. This means three-quarters of the company’s income comes from other sources.

The remaining revenue splits between two categories: services (roughly 15% of sales) and instruments plus accessories (approximately 60%). This composition reveals the true financial engine of the business. Each surgical robot installed becomes a revenue generator for years. Around 75% of overall revenue is recurring—more akin to a subscription model than a one-time transaction.

Why does this matter? Usage intensity directly impacts profitability. When more procedures are performed with existing da Vinci systems, the company captures additional instrument and accessory sales without deploying new capital. In 2025, surgical procedures performed with the company’s robots increased 18% compared to 2024—a rate far exceeding the installed base growth rate. This demonstrates robust market demand for the technology itself, not merely demand for the hardware.

Artificial Intelligence as the Next Growth Catalyst

Looking forward, the company’s integration of artificial intelligence into its platform represents a significant opportunity. Late in 2025, the FDA approved an AI tool designed to provide real-time visual enhancements during lung biopsy procedures. While this may appear incremental, it addresses a genuine surgical challenge: lungs move constantly during procedures, rendering pre-operative imaging obsolete by the time surgery begins.

This approval signals the regulatory pathway is opening. The logical question investors should consider when analyzing intuitive stocks involves AI’s broader potential. Could surgical robotics eventually become largely autonomous? The technology trajectory suggests this is plausible, even if full autonomy remains years away.

The Valuation Question Every Investor Must Face

Wall Street has clearly recognized Intuitive’s opportunity. The stock currently trades at a price-to-earnings ratio near 67 times—more than double the S&P 500’s current P/E of approximately 28 times. For value-oriented investors, this represents a significant hurdle.

Context matters, however. Over the past five years, Intuitive has averaged a P/E ratio near 72 times. By that measure, the current valuation appears relatively modest. The broader growth stock category, as represented by the Vanguard Growth ETF, trades at a P/E ratio just under 40 times. So while Intuitive commands a premium to the general market and even to typical growth stocks, it trades at a discount to its own historical range.

The critical question becomes: Is that premium justified? This depends entirely on your conviction regarding the company’s long-term growth rate. For investors who believe surgical robotics will become increasingly central to healthcare delivery and that Intuitive maintains its market position, the multiple may represent reasonable compensation. For skeptics, the valuation offers little margin of safety.

Preparing for the Long Journey

If you commit capital to intuitive stocks, you must mentally prepare for volatility. Drawdowns exceeding 30% occur periodically. Short-term traders often regret their entry point, while patient investors who establish positions and hold through downturns have historically been rewarded.

One practical consideration: if you find the current valuation troubling, it may be prudent to wait for a more significant market correction before establishing a position. These stocks occasionally experience severe pullbacks that create more attractive entry points. Buying when fear dominates the market, rather than when enthusiasm prevails, often proves the wiser course.

The Final Assessment

Intuitive Surgical operates in an expanding market with genuine competitive moats. Its recurring revenue model creates business stability, and AI integration opens fresh growth avenues. The fundamental business is healthy, and execution has been solid.

The challenge isn’t the company—it’s the price. When you buy intuitive stocks today, you’re not just purchasing a business; you’re paying for expected growth years into the future. That’s a reasonable trade for patient, disciplined investors with a multi-year horizon. For those seeking bargains or quick returns, more attractive opportunities almost certainly exist elsewhere.